Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunochemotherapy and temozolomide maintenance in elderly patients with primary central nervous system lymphoma
2006-004772-12Phase 2Completed
- Sponsor
- Nordic Lymphoma Group
- Start
- Nov 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in primary central nervous system lymphoma (PCNSL), sponsored by Nordic Lymphoma Group. Primary endpoint: Efficacy and safety after completion of induction therapy. Started Nov 2006; status: completed.
02
Drugs
temozolomide
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on 2006-004772-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004772-12.